The pivotal role played by device developers to improve patient eye care

The pivotal role played by device developers to improve patient eye care

Novelia, our preservative-free multidose eye dropper, that addresses the challenges of patients suffering from glaucoma & dry eye diseases.

POST-8

Our ophthalmic experts discuss the challenges glaucoma and dry eye patients face with eye drop administration and present the Novelia® system featuring patented PureFlow® technology, which controls the medication flow.

Dry eye disease is among the most common diseases in ophthalmology, with a prevalence of between 5% and 34%. Studies from specialist centres have found higher prevalence of up to 57%. Dry eye leads to more frequent patient-doctor contact than glaucoma.
Glaucoma is a chronic, progressive optic neuropathy and a leading cause of blindness. In 2020, it was estimated that approximately 80 million people have glaucomaworldwide, and this number is expected to increase to over 111 million by 2040. An increase in teleworking as a result of covid-19 has been a contributing factor to an increase in “digital eye strain”.

During the study, patients commonly cited two key challenges relating to eye drop administration, the first of which being lack of control. Another challenge cited by patients was the uncertainty around remaining drops.

Novelia’s patented PureFlow® technology not only serves as a venting system but also controls the medication flow. Nemera has adapted the flow control within Novelia® that avoids multiple drop delivery into the eye and ensures that only one calibrated drop is dispensed at a time.
Nemera offers three different PureFlow® versions, each tailored to formulations of differing viscosities, from highly liquid to highly viscous. In addition, five different valve sizes are available, each one delivering a different calibrated drop size. This allows Nemera to customise the drop size
depending on specific product requirements. This improved control leads to increased patient confidence (of accurate dosing), and reduced frustration and medication waste.

To serve customers in supporting patient needs, Nemera has recently extended its manufacturing capabilities and, in doing so, has doubled its capacity to produce the Novelia® preservative-free multidose eyedropper.

You want to know more? Drop in to say hello to us at ARVO


To read the full article: Ophthalmic Drug Delivery – April issue 118 – Nemera

To read the full magazine: Ophthalmic Drug Delivery – April issue 118


About the author:

Zoe Davidson is the Global Category Manager for Nemera’s ophthalmic franchise, including the preservative-free multidose eyedropper, Novelia®. Mrs Davidson joined Nemera in January 2017 as part of the business development team, responsible for ophthalmic products, before transitioning into the category manager role during the summer of 2019.

Carolyn Rose is the Leader of Design Research at Nemera’s Insight Innovation Centre, where research is leveraged to better understand the patient journey and user needs to help inform product development for both Nemera and global clients. Ms Rose has worked for nearly 20 years in design research, generating meaningful insights and defining actionable market opportunities. Her human-centred and process-oriented approach aims to better understand the behaviours, expectations and motivations of end users, as well as the environments, attitudes and trends that shape them.

About Nemera

As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit www.nemera.net